List of Excipients in Branded Drug INTERMEZZO

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Purdue Pharma LP	INTERMEZZO	zolpidem tartrate	59011-256	CROSCARMELLOSE SODIUM
Purdue Pharma LP	INTERMEZZO	zolpidem tartrate	59011-256	CROSPOVIDONE
Purdue Pharma LP	INTERMEZZO	zolpidem tartrate	59011-256	FERRIC OXIDE YELLOW
Purdue Pharma LP	INTERMEZZO	zolpidem tartrate	59011-256	MANNITOL
Purdue Pharma LP	INTERMEZZO	zolpidem tartrate	59011-256	SILICON DIOXIDE

Intermezzo Excipient Strategy and Commercial Opportunities for Zolpidem Sublingual Tablets

Last updated: September 24, 2026

Intermezzo is a low-dose sublingual zolpidem tartrate tablet developed for patients who awaken during the night and have at least four hours remaining before planned awakening. Its commercial differentiation depends on rapid oral disintegration, acceptable taste, low tablet mass, dose uniformity at 1.75 mg and 3.5 mg, and controlled-substance manufacturing controls. The strongest excipient opportunities are in directly compressible mannitol systems, superdisintegrants, taste-masking technologies, lubricant selection, and platform formulations that support generic or 505(b)(2) development.

What is Intermezzo and how does its formulation create commercial value?

Intermezzo contains zolpidem tartrate in 1.75 mg and 3.5 mg sublingual tablet strengths. The FDA approved the product in 2011 for middle-of-the-night insomnia when the patient has at least four hours available for sleep. It is administered under the tongue and is not intended to replace standard bedtime zolpidem products. [1]

The product’s formulation value comes from delivery performance rather than a novel active ingredient. Zolpidem is an established nonbenzodiazepine hypnotic, but the sublingual dosage form addresses a narrower use case:

• Rapid drug release without water.
• Low unit dose suitable for nighttime redosing.
• Small, orally disintegrating tablet.
• Acceptable mouthfeel and taste.
• Consistent performance despite low active loading.
• Compatibility with a Schedule IV controlled substance.

The low active-to-excipient ratio creates a meaningful formulation challenge. In the 1.75 mg strength, most of the tablet mass consists of excipients. Small changes in blend uniformity, particle size, segregation, or lubrication can materially affect dose accuracy and disintegration.

What excipients are used in Intermezzo?

The FDA-approved labeling identifies a multifunctional excipient system that includes mannitol, microcrystalline cellulose, colloidal silicon dioxide, sodium starch glycolate, sucralose, and magnesium stearate. The exact commercial composition and manufacturing parameters should be evaluated against the current prescribing information and regulatory filings. [1,2]

Excipient class	Intermezzo role	Commercial formulation objective
Mannitol	Diluent and mouthfeel modifier	Provides a cooling, low-moisture base suitable for oral disintegration
Microcrystalline cellulose	Filler and dry-binding aid	Supports tablet strength and content uniformity
Sodium starch glycolate	Superdisintegrant	Accelerates tablet breakup and drug release
Colloidal silicon dioxide	Glidant and flow aid	Improves powder flow and reduces segregation risk
Sucralose	High-intensity sweetener	Reduces bitterness from zolpidem
Magnesium stearate	Lubricant	Controls ejection force and tooling adhesion

Why mannitol is commercially important

Mannitol is well suited to sublingual and orally disintegrating products because it has a relatively pleasant taste, low hygroscopicity compared with many polyols, and a cooling sensation in the mouth. It is available in grades designed for direct compression and quick-dissolving tablets.

For an Intermezzo-type product, the relevant supplier attributes are:

• Consistent particle-size distribution.
• Low and controlled moisture.
• High compactability.
• Low friability after compression.
• Reliable supply of pharmaceutical-grade material.
• Qualification for direct-compression processing.

Mannitol creates an opportunity for excipient suppliers to sell not only commodity material but also co-processed or engineered grades optimized for sublingual tablet manufacture.

Why superdisintegrant selection matters

Sodium starch glycolate supports rapid tablet breakup after contact with saliva. Its performance depends on particle size, degree of substitution, concentration, compression force, and the hydrophobicity introduced by magnesium stearate.

Potential development variables include:

• Sodium starch glycolate versus crospovidone.
• Intragranular versus extragranular addition.
• Total superdisintegrant concentration.
• Disintegration under limited saliva volume.
• Drug release after compression at commercial scale.

Crospovidone is a credible alternative in a development program because it provides rapid wicking and is less dependent on swelling than sodium starch glycolate. It can also support lower-moisture processing. A formulation change that preserves rapid sublingual release while improving mechanical strength could support a differentiated generic or a 505(b)(2) product.

What formulation patents protect Intermezzo-type products?

Intermezzo-type products may be protected by patents covering low-dose zolpidem compositions, sublingual administration, dosage strengths, release characteristics, and methods for treating middle-of-the-night awakening. The active ingredient itself is no longer the principal barrier. The relevant IP questions concern dosage form, use, formulation performance, and regulatory exclusivity.

A freedom-to-operate review should examine:

1. Orange Book-listed patents for the approved Intermezzo product.
2. Patent families assigned to Transcept Pharmaceuticals, Purdue entities, or related rights holders.
3. Continuation and divisional applications covering sublingual zolpidem.
4. Patents claiming specific excipient combinations.
5. Method-of-use claims covering administration after nocturnal awakening.
6. Patent-term-adjustment and patent-term-extension calculations.
7. Any terminal disclaimers linking later patents to earlier patent families.

A generic applicant cannot assume that a formulation using different excipients avoids infringement. Claims may be drafted around functional characteristics, dosage strength, administration timing, or pharmacokinetic performance rather than a named excipient.

What is the Orange Book and FDA regulatory status of Intermezzo?

Intermezzo was approved through an NDA under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act. The FDA approval established the product’s safety, efficacy, dosage strengths, and labeling for middle-of-the-night insomnia. [1]

The product is a zolpidem-containing Schedule IV controlled substance. Any commercial launch must address:

• Controlled-substance registration.
• Security and inventory controls.
• DEA manufacturing and distribution requirements.
• Abuse-deterrence and diversion controls applicable to the product category.
• Accurate tablet-strength segregation.
• Stability and content-uniformity controls.
• Labeling restrictions associated with zolpidem and next-day impairment.

The FDA Orange Book remains the principal source for listed patents and exclusivity information. [3] Because Orange Book entries and patent litigation records can change, the operative analysis must use the current edition and the applicable FDA patent-listing records.

How does a generic applicant challenge Intermezzo?

A 505(j) applicant could pursue an abbreviated new drug application if it can demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. The principal certification pathways are:

• Paragraph I: no patent information is listed.
• Paragraph II: listed patent has expired.
• Paragraph III: applicant will wait until patent expiration.
• Paragraph IV: listed patent is invalid, unenforceable, or will not be infringed.

A Paragraph IV notice can trigger patent litigation under 35 U.S.C. §271(e)(2). The litigation may delay FDA approval for up to 30 months, subject to statutory exceptions and court developments. [4]

For a sublingual product, bioequivalence strategy can be more complex than for a conventional oral tablet. The applicant must control:

• Sublingual disintegration.
• Early drug release.
• Saliva-mediated dissolution.
• Tablet placement and administration instructions.
• Comparative pharmacokinetic exposure.
• Possible food and alcohol effects.
• Dose proportionality between 1.75 mg and 3.5 mg.

A generic developer may attempt a formulation that uses the same inactive ingredients in different quantities or a different excipient system. That approach can simplify comparative product development, but it may increase infringement risk if the reference product’s claims are not limited to specific excipients.

What excipient opportunities exist for generic and 505(b)(2) developers?

Direct-compression excipient platforms

The most immediate opportunity is a directly compressible mannitol platform that combines:

• High compactability.
• Fast wetting.
• Low friability.
• Consistent low-dose blend uniformity.
• Low moisture uptake.
• Pleasant mouthfeel.

A supplier that provides a validated excipient blend can reduce development time for companies entering the sublingual zolpidem market and adjacent products such as sublingual sedatives, rescue therapies, and fast-dissolving CNS medicines.

Taste-masking systems

Zolpidem has a bitter taste profile. Sucralose alone may not fully address bitterness under sublingual exposure because the drug dissolves rapidly in a small volume of saliva. Commercial opportunities include:

• Ion-exchange resin complexes.
• Polymer film coatings.
• Lipid-based taste masking.
• pH-modifying excipient systems.
• Multi-sweetener systems.
• Flavored mannitol platforms.

Taste masking must not slow sublingual release or increase tablet size. A coating that works in a swallowed orally disintegrating tablet may perform poorly under the tongue if it produces delayed drug release or an objectionable residue.

Co-processed excipients

Co-processed systems can combine mannitol with microcrystalline cellulose, crospovidone, or another disintegration aid. The commercial value is process simplification. A single engineered excipient can reduce the number of formulation variables and improve blend uniformity for a low-dose controlled substance.

The main technical risks are:

• Proprietary excipient composition.
• Higher cost per tablet.
• Supplier qualification burden.
• Limited regulatory precedent.
• Potential need for additional characterization in an ANDA.
• Risk that the co-processed material changes dissolution or bioequivalence.

Lubricant alternatives

Magnesium stearate is effective but can reduce wetting and delay disintegration when overmixed or used at excessive concentration. Alternatives such as sodium stearyl fumarate may provide a development path for faster wetting and lower hydrophobicity.

The commercial opportunity is strongest where the alternative lubricant improves:

• Ejection force.
• Tablet hardness.
• Disintegration time.
• Dissolution variability.
• Manufacturing robustness at high-speed compression.

How strong is the patent estate for Intermezzo?

The estate should be analyzed as a layered portfolio rather than as a single patent block.

Protection layer	Relevance to Intermezzo	Generic risk
Active-ingredient patents	Limited for established zolpidem	Low
Sublingual formulation patents	Potentially important	Moderate to high
Method-of-use patents	May cover nocturnal awakening or dosing timing	Moderate
Dosage-strength claims	Relevant to 1.75 mg and 3.5 mg products	Moderate
Manufacturing claims	Could restrict specific processing routes	Low to moderate
Orange Book-listed patents	Can trigger Paragraph IV litigation	High if unexpired
Regulatory exclusivity	Depends on FDA designation and approval history	Historical importance
Trademark and trade dress	Commercial rather than scientific protection	Low for ANDA approval

The formulation estate is strongest when claims combine a specific dosage strength, sublingual administration, rapid release, and a defined therapeutic use. A generic company may avoid some claims through a different excipient system, but doing so can introduce bioequivalence and taste-masking risk.

When does Intermezzo lose exclusivity and face generic entry?

Generic-entry timing depends on the current Orange Book listings, patent expiration dates, pediatric exclusivity, litigation outcomes, and any settlement agreements. The original approval date alone does not establish the current generic-entry date.

A practical exclusivity timeline is:

Event	Commercial consequence
NDA approval in 2011	Established the reference listed drug
Initial market exclusivity period	Delayed certain ANDA approvals
Orange Book patent listings	Determined whether Paragraph IV certification was available
Paragraph IV notice	Could initiate patent litigation and a 30-month stay
Patent expiration or successful invalidity decision	Opened the principal route to generic launch
ANDA approval	Did not necessarily guarantee immediate commercial launch
Controlled-substance supply qualification	Added a manufacturing and distribution barrier

No broad biosimilar pathway applies to Intermezzo. Zolpidem is a chemically synthesized small molecule, so competitive entry would come through ANDAs or, for materially different products, 505(b)(2) applications rather than biosimilar applications.

Which companies are positioned to challenge Intermezzo?

The likely competitive field consists of:

• Generic manufacturers with existing zolpidem portfolios.
• Companies specializing in orally disintegrating tablets.
• Controlled-substance manufacturers with DEA infrastructure.
• Contract development and manufacturing organizations with low-dose direct-compression capabilities.
• Excipient suppliers offering ready-to-use fast-disintegrating platforms.

The strongest entrants would combine ANDA regulatory experience, controlled-substance manufacturing capacity, sublingual formulation expertise, and reliable supply of pharmaceutical-grade mannitol and superdisintegrants.

What generic launch scenarios exist?

Scenario 1: Same-core excipient formulation

A developer uses mannitol, microcrystalline cellulose, sodium starch glycolate, sweetener, glidant, and lubricant. This may simplify product development and reduce bioequivalence risk. It may also create higher patent exposure if formulation claims cover the excipient combination or functional performance.

Scenario 2: Alternative superdisintegrant and lubricant

A developer replaces sodium starch glycolate or magnesium stearate with crospovidone or sodium stearyl fumarate. This may reduce literal infringement risk and improve disintegration, but it requires comparative dissolution, mechanical-strength, and pharmacokinetic work.

Scenario 3: 505(b)(2) reformulation

A company develops a modified sublingual zolpidem product with a new taste-masking system, altered dose, or different release profile. This route may support product differentiation but carries higher clinical, regulatory, and patent costs than a conventional ANDA.

Scenario 4: Limited commercial launch

A generic company launches one or both strengths with restricted distribution because of controlled-substance requirements. The product may achieve regulatory entry without quickly matching the reference product’s commercial reach.

What commercial opportunities exist beyond Intermezzo?

The excipient platform has applications beyond zolpidem:

• Sublingual analgesics.
• Emergency cardiovascular medicines.
• Antiemetics.
• Migraine products.
• Hormonal therapies.
• CNS rescue medicines.
• Pediatric orally disintegrating products.
• Veterinary sublingual or buccal medicines.

The most attractive opportunity is a modular platform that supports rapid disintegration, taste masking, and low-dose uniformity across multiple active ingredients. A supplier can create value through formulation support, regulatory documentation, and scale-up assistance rather than through raw-material sales alone.

Key Takeaways

• Intermezzo’s commercial differentiation is its low-dose sublingual delivery of zolpidem for middle-of-the-night awakening.
• Mannitol, microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, sucralose, and magnesium stearate form the core excipient strategy identified in public labeling.
• The main technical barriers are taste, rapid disintegration, low-dose uniformity, tablet strength, and controlled-substance manufacturing.
• The most attractive excipient opportunities are engineered mannitol systems, co-processed direct-compression excipients, taste-masking technologies, and less-hydrophobic lubricants.
• Generic entry depends on current Orange Book listings, Paragraph IV certifications, patent litigation, settlement terms, and FDA approval timing.
• Biosimilar competition is not relevant because zolpidem is a small-molecule active ingredient.
• A 505(b)(2) product could create differentiation through taste masking, modified dose, or altered sublingual performance, but it would carry greater regulatory and clinical risk than an ANDA.
• The strongest commercial platform is a scalable, low-moisture, fast-disintegrating excipient system that can be used across several sublingual and orally disintegrating medicines.

FAQs

Can mannitol alone provide adequate Intermezzo-like tablet performance?

No. Mannitol can provide the diluent and mouthfeel base, but a complete formulation normally requires a binder or compactability aid, superdisintegrant, glidant, lubricant, and taste-masking component.

Is Intermezzo eligible for biosimilar competition?

No. Zolpidem is a chemically synthesized small molecule. Competition proceeds through the ANDA pathway or, for materially different products, the 505(b)(2) pathway.

Which excipient is most important for sublingual disintegration?

The superdisintegrant is usually the principal disintegration driver, but performance depends on its interaction with mannitol, tablet compression force, lubricant concentration, moisture, and particle-size distribution.

Can a generic use different excipients from Intermezzo?

Yes, subject to FDA pharmaceutical-equivalence and bioequivalence requirements. A different excipient system may reduce patent risk but can increase formulation and bioequivalence development risk.

Does controlled-substance status create an excipient business opportunity?

Yes. Suppliers that support validated blend uniformity, low-dose content control, tamper-resistant packaging, and documented pharmaceutical-grade supply can reduce operational risk for manufacturers handling zolpidem products.

References

1. U.S. Food and Drug Administration. (2011). Intermezzo (zolpidem tartrate) sublingual tablets: Prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: Intermezzo, zolpidem tartrate sublingual tablet.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
4. U.S. Food and Drug Administration. (2013). Guidance for industry: 180-day exclusivity when multiple first applicants are eligible for 180-day exclusivity.